Argenx Se (ARGX) Research & Development (2016 - 2026)
Argenx Se (ARGX) posted Research & Development of -$443.0 million for Q1 2026, down 19.18% on a QoQ basis from -$371.7 million in Q4 2025, and down 42.44% year-over-year from -$769.7 million in Q1 2025.
Argenx Se (ARGX) Research & Development (2016 - 2026) Analysis & Trends
Argenx Se's Research & Development history runs 11 years deep, the most recent figure standing at -$443.0 million for Q1 2026.
- Quarterly Research & Development fell 42.44% year-over-year to -$443.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.5 billion (down 40.08% YoY) and the FY2025 annual result came in at $1.4 billion, up 38.71% from the prior year.
- Research & Development was -$443.0 million for Q1 2026 at Argenx Se, down from -$371.7 million in the prior quarter.
- Across five years, Research & Development topped out at -$126.9 million in Q2 2022 and bottomed at -$443.0 million in Q1 2026.
- A 5-year average of -$253.8 million and a median of -$235.9 million in 2024 frame the typical range for Research & Development.
- Peak annual rise in Research & Development reached 18.98% in 2023, while the deepest fall reached 107.29% in 2023.
- Argenx Se's Research & Development stood at -$147.8 million in 2022, then plunged by 107.29% to -$306.4 million in 2023, then grew by 2.98% to -$297.2 million in 2024, then dropped by 25.06% to -$371.7 million in 2025, then fell by 19.18% to -$443.0 million in 2026.
- Business Quant data shows ARGX's Research & Development at -$443.0 million in Q1 2026, -$371.7 million in Q4 2025, and -$355.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 364.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -443.00 Mn |
| Dec 31, 2025 | -371.71 Mn |
| Sep 30, 2025 | -355.65 Mn |
| Jun 30, 2025 | -327.70 Mn |
| Mar 31, 2025 | -311.00 Mn |
| Dec 31, 2024 | -297.23 Mn |
| Sep 30, 2024 | -235.94 Mn |
| Jun 30, 2024 | -225.29 Mn |
| Mar 31, 2024 | -224.97 Mn |
| Dec 31, 2023 | -306.37 Mn |
| Sep 30, 2023 | -191.76 Mn |
| Jun 30, 2023 | -195.51 Mn |
| Mar 31, 2023 | -165.86 Mn |
| Dec 31, 2022 | -147.80 Mn |
| Sep 30, 2022 | -236.68 Mn |
| Jun 30, 2022 | -126.92 Mn |
| Mar 31, 2022 | -151.97 Mn |
| Dec 31, 2021 | -167.17 Mn |
| Sep 30, 2021 | -139.44 Mn |
| Jun 30, 2021 | -151.58 Mn |